New insulin lyumjev tested for safety in indian diabetes patients
NCT ID NCT06370715
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 36 times
Summary
This study tested the safety of Lyumjev, a rapid-acting insulin, in 150 adults with type 2 diabetes in India. Participants used Lyumjev along with their usual long-acting insulin for 26 weeks. The main goal was to see how many people had low blood sugar episodes. The study is already completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brij Medical Center Pvt. Ltd.
Kanpur, Uttar Pradesh, 208020, India
-
Center for Diabetes and Endocrine Care
Bengaluru, Karnataka, 560043, India
-
Chellaram Diabetes Institute
Pune, Maharashtra, 411021, India
-
Diabetes Research Centre
Royapuram, Chennai India, 600013, India
-
King George Hospital, Visakhapatnam
Visakhapatnam, Andhra Pradesh, 530002, India
-
Kovai Diabetes Speciality Center and Hospital
Coimbatore, Tamil Nadu, 641009, India
-
Medical College & Hospital, Kolkata
Kolkata, West Bengal, 700073, India
-
Osmania Medical College & Hospital
Hyderabad, Andhra Pradesh, 500012, India
-
Rajasthan University of Health Sciences
Jaipur, Rajasthan, 302033, India
-
S. P. Medical College & A G Hospital
Bikaner, Rajasthan, 334003, India
-
Sahyadri Super Speciality Hospital
Pune, Maharashtra, 411004, India
-
Vijyaratna Dibetes Diagnosis Treatment Centre
Ahmedabad, Gujarat, 380007, India
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lyumjev (insulin lispro-aabc) and insulin glargine
What this could lead to
If successful, this study could confirm that Lyumjev is a safe option for managing blood sugar in adults with type 2 diabetes in India.
What could go wrong
This is a single-arm, open-label study with no comparison group, so results may not be definitive. Hypoglycemia (low blood sugar) is a known risk with insulin therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.